Browsing Bergen Open Research Archive by Author "Bø, Lars"

Now showing items 1-20 of 22

    • Adverse events with fatal outcome associated with alemtuzumab treatment in multiple sclerosis 

      Holmøy, Trygve; Fevang, Børre; Olsen, David Benee; Spigset, Olav; Bø, Lars (Peer reviewed; Journal article, 2019-08-12)
      Objective: Sporadic fatal adverse events have been reported during treatment of multiple sclerosis with alemtuzumab. To provide a systematic overview, we searched the centralized European Medicines Agency database of ...

    • An Association of Chitinase-3 Like-Protein-1 With Neuronal Deterioration in Multiple Sclerosis 

      Ahmad, Intakhar; Wergeland, Stig; Oveland, Eystein; Bø, Lars (Journal article; Peer reviewed, 2023)
      Elevated levels of Chitinase-3-like protein-1 (CHI3L1) in cerebrospinal fluid have previously been linked to inflammatory activity and disease progression in multiple sclerosis (MS) patients. This study aimed to investigate ...

    • Cuprizone and EAE mouse frontal cortex proteomics revealed proteins altered in multiple sclerosis 

      Oveland, Eystein; Ahmad, Intakhar; Lereim, Ragnhild Reehorst; Kroksveen, Ann Cathrine; Barsnes, Harald; Guldbrandsen, Astrid; Myhr, Kjell-Morten; Bø, Lars; Berven, Frode Steingrimsen; Wergeland, Stig (Journal article; Peer reviewed, 2021)
      Two pathophysiological different experimental models for multiple sclerosis were analyzed in parallel using quantitative proteomics in attempts to discover protein alterations applicable as diagnostic-, prognostic-, or ...

    • Dietary Vitamin D3 Supplements Reduce Demyelination in the Cuprizone Model 

      Wergeland, Stig; Torkildsen, Øivind; Myhr, Kjell-Morten; Aksnes, Lage; Mørk, Sverre; Bø, Lars (Peer reviewed; Journal article, 2011-10-20)
      Vitamin D is emerging as a probably important environmental risk factor in multiple sclerosis, affecting both susceptibility and disease progression. It is not known to what extent this effect is due to a modulation of ...

    • Disease-modifying treatments for multiple sclerosis – a review of approved medications 

      Torkildsen, Øivind; Myhr, Kjell-Morten; Bø, Lars (Peer reviewed; Journal article, 2015-11-13)
      Background and purpose: There is still no curative treatment for multiple sclerosis (MS), but during the last 20 years eight different disease-modifying compounds have been approved for relapsing remitting MS (RRMS). ...

    • The economic impact of multiple sclerosis to the patients and their families in Norway 

      Svendsen, Bjørn; Grytten, Nina; Bø, Lars; Aarseth, Hallvard Gilje; Smedal, Tori; Myhr, Kjell-Morten (Peer reviewed; Journal article, 2018-12)
      Background: Multiple sclerosis (MS) imposes high economic costs on society, but the patients and their families have to bear some of these costs. Objective: We aimed to estimate the magnitude of these economic costs in ...

    • The effect of gadolinium-based contrast-agents on automated brain atrophy measurements by FreeSurfer in patients with multiple sclerosis 

      Lie, Ingrid Anne; Kerklingh, Emma; Wesnes, Kristin; van Nederpelt, David R.; Brouwer, Iman; Torkildsen, Øivind; Myhr, Kjell-Morten; Barkhof, Frederik; Bø, Lars; Vrenken, Hugo (Journal article; Peer reviewed, 2022)
      Objective To determine whether reliable brain atrophy measures can be obtained from post-contrast 3D T1-weighted images in patients with multiple sclerosis (MS) using FreeSurfer. Methods Twenty-two patients with MS ...

    • The Effect of Smoking on Long-term Gray Matter Atrophy and Clinical Disability in Patients with Relapsing-Remitting Multiple Sclerosis 

      Lie, Ingrid Anne; Wesnes, Kristin; Kvistad, Silje S.; Brouwer, Iman; Wergeland, Stig; Holmøy, Trygve; Midgard, Rune; Bru, Alla Nikolajevna S; Edland, Astrid; Eikeland, Randi; Gosal, Sonia; Harbo, Hanne-Cathrin Flinstad; Kleveland, Grethe; Sørenes, Yvonne; Øksendal, Nina; Barkhof, Frederik; Vrenken, Hugo; Myhr, Kjell-Morten; Bø, Lars; Torkildesen, Øivind (Journal article; Peer reviewed, 2022)
      Background and Objectives The relationship between smoking, long-term brain atrophy, and clinical disability in patients with multiple sclerosis (MS) is unclear. Here, we assessed long-term effects of smoking by evaluating ...

    • Employment among patients with multiple sclerosis - A population study 

      Lunde, Hanne Marie; Telstad, Wenche; Torkildsen, Nina Agnethe Grytten; Kyte, Lars; Aarseth, Jan; Myhr, Kjell-Morten; Bø, Lars (Peer reviewed; Journal article, 2014-07-23)

    • Fingolimod does not enhance cerebellar remyelination in the cuprizone model 

      Alme, Maria Nordheim; Nystad, Agnes Elisabeth; Bø, Lars; Myhr, Kjell-Morten; Vedeler, Christian A.; Wergeland, Stig; Torkildsen, Øivind (Journal article, 2015-08)
      Fingolimod (FTY720) is approved for treatment of relapsing–remitting multiple sclerosis. In vitro studies have found that fingolimod stimulates remyelination in cerebellar slices, but in vivo animal studies have not detected ...

    • A higher proportion of ermin-immunopositive oligodendrocytes in areas of remyelination 

      Ahmad, Intakhar; Wergeland, Stig; Oveland, Eystein; Bø, Lars (Journal article; Peer reviewed, 2021)
      Incomplete remyelination is frequent in multiple sclerosis (MS)-lesions, but there is no established marker for recent remyelination. We investigated the role of the oligodendrocyte/myelin protein ermin in de- and remyelination ...

    • Impact of previous disease-modifying treatment on safety and efficacy in patients with MS treated with AHSCT 

      Stokke, Silje Agnethe; Burman, Joachim; Lehmann, Anne Kristine; Tolf, Andreas; Zjukovskaja, Christina; Melve, Guro Kristin; Bø, Lars; Torkildsen, Øivind (Journal article; Peer reviewed, 2022)
      Background Autologous haematopoietic stem cell transplantation (AHSCT) is a highly effective treatment for multiple sclerosis (MS). The impact of previous long-lasting disease-modifying treatments (DMT) for safety and ...

    • Magnetization transfer ratio does not correlate to myelin content in the brain in the MOG-EAE mouse model 

      Fjær, Sveinung; Bø, Lars; Myhr, Kjell-Morten; Torkildsen, Øivind; Wergeland, Stig (Peer reviewed; Journal article, 2015-03-02)
      Magnetization transfer ratio (MTR) is a magnetic resonance imaging (MRI) method which may detect demyelination not detected by conventional MRI in the central nervous system of patients with multiple sclerosis (MS). A ...

    • The neuroprotective potential of mesenchymal stem cells from bone marrow and human exfoliated deciduous teeth in a murine model of demyelination 

      Kråkenes, Torbjørn; Wergeland, Stig; Al-Sharabi, Niyaz Abdulbaqi Abdulmajid; Mohamed-Ahmed, Samih Salah Eldin Mahgoub; Fromreide, Siren; Costea, Daniela Elena; Mustafa, Kamal Babikeir Elnour; Bø, Lars; Kvistad, Christopher Elnan (Journal article; Peer reviewed, 2023)
      Introduction Multiple sclerosis (MS) is characterized by chronic inflammation, demyelination, and axonal degeneration within the central nervous system (CNS), for which there is no current treatment available with the ...

    • Poor Sleep in Patients with Multiple Sclerosis 

      Lunde, Hanne Marie Bøe; Aae, Tommy F.; Indrevåg, William; Aarseth, Jan Harald; Bjorvatn, Bjørn; Myhr, Kjell-Morten; Bø, Lars (Peer reviewed; Journal article, 2012-11-14)
      Background: Poor sleep is a frequent symptom in patients with multiple sclerosis (MS). Sleep may be influenced by MS-related symptoms and adverse effects from immunotherapy and symptomatic medications. We aimed to study ...

    • Predictors of hospitalization due to infection in rituximab-treated MS patients 

      Karlowicz, Jakob Rishovd; Klakegg, Mattias; Aarseth, Jan Harald; Bø, Lars; Myhr, Kjell-Morten; Torgauten, Hilde Marie; Torkildsen, Øivind; Wergeland, Stig (Journal article; Peer reviewed, 2023)
      Background: Rituximab is extensively used off-label to treat multiple sclerosis (MS), and long-term vigilance for adverse events is needed. This study was conducted to determine frequencies and predictors of hematological ...

    • Relationship between White Matter Lesions and Gray Matter Atrophy in Multiple Sclerosis 

      Lie, Ingrid Anne; Weeda, Merlin M.; Mattiesing, Rozemarijn M.; Mol, Marijke A.E.; Pouwels, Petra J.W.; Barkhof, Frederik; Torkildsen, Øivind; Bø, Lars; Myhr, Kjell-Morten; Vrenken, Hugo (Journal article; Peer reviewed, 2022)
      Background and Objectives: There is currently no consensus about the extent of gray matter (GM) atrophy that can be attributed to secondary changes after white matter (WM) lesions or the temporal and spatial relationships ...

    • Safety and Clinical Efficacy of Mesenchymal Stem Cell Treatment in Traumatic Spinal Cord Injury, Multiple Sclerosis and Ischemic Stroke – A Systematic Review and Meta-Analysis 

      Kvistad, Christopher Elnan; Kråkenes, Torbjørn; Gjengedal, Gudveig Cecilie Gjerde; Mustafa, Kamal Babikeir Elnour; Rekand, Tiina; Bø, Lars (Journal article; Peer reviewed, 2022-05-30)
      Background: Mesenchymal stem cells (MSCs) is an attractive candidate in regenerative research and clinical trials have assessed their therapeutic potential in different neurological conditions with disparate etiologies. ...

    • Safety and efficacy of rituximab as first- and second line treatment in multiple sclerosis – A cohort study 

      Torgauten, Hilde Marie; Myhr, Kjell-Morten; Wergeland, Stig; Bø, Lars; Aarseth, Jan Harald; Torkildsen, Øivind (Journal article; Peer reviewed, 2021-01-31)
      Background Rituximab is increasingly used as off-label therapy in multiple sclerosis (MS). More data are needed on safety and efficacy of rituximab, particularly in cohorts of de novo patients and patients in early therapy ...

    • Safety of breast feeding during rituximab treatment in multiple sclerosis 

      Rød, Brit Ellen; Torkildsen, Øivind; Myhr, Kjell-Morten; Bø, Lars; Wergeland, Stig (Journal article; Peer reviewed, 2022)
      Background There are limited data on the safety of breast feeding during rituximab therapy. Our objective is to determine exposure from breast feeding and biological effects of rituximab in breastfed infants. Methods ...